– Curewell Capital (“Curewell”), a private equity firm focused on middle-market healthcare companies, closed Curewell Capital I, LP (and related vehicles, the “Fund”) at its hard cap of $535 million.
– The inaugural Fund was raised in a single closing, completing less than five months after launch.
– Commitments were secured from a diverse group of global institutional investors, including endowments, foundations, pensions, insurance companies, consultants, family offices, and industry executives.
– Curewell is led by Michael Dal Bello and Ceron Rhee, who have nearly two decades of shared experience, including at Blackstone and Pritzker Private
Capital, where they led the healthcare investment practice.
– The Fund follows the team’s strategy of acquiring leading U.S. healthcare businesses across healthcare services, pharmaceutical services, medical devices, and healthcare technology.
– Curewell aims to partner with experienced founders and management teams to accelerate growth and operational performance of healthcare companies.
– Michael Dal Bello stated that the firm is grateful for investor trust and looks forward to building lasting value while improving access, reducing costs, and enhancing quality of care.
– Ceron Rhee emphasized that the Fund represents a new chapter in supporting teams driving innovation and transformation in healthcare, with strong opportunities to improve outcomes and efficiencies across the U.S. healthcare system.
– Probitas Partners acted as exclusive placement advisor for the Fund.
– Kirkland & Ellis LLP served as fund counsel.
